The outcome of COVID-19 in patients with hematological malignancy

Basit Öğe Kaydı
dc.authoridYigenoglu, Tugce/0000-0001-9962-8882
dc.authoridErkurt, Mehmet Ali/0000-0002-3285-417X
dc.authoridBasturk, Abdulkadir/0000-0003-1864-0316
dc.authoridBaşcı, Semih/0000-0003-4304-9245
dc.authoridDogu, Mehmet Hilmi/0000-0001-7237-2637
dc.authoridBERBER, Ilhami/0000-0003-3312-8476
dc.authoridBirinci, Suayip/0000-0001-8104-6198
dc.authorwosidYigenoglu, Tugce/ABF-6595-2021
dc.authorwosidErkurt, Mehmet Ali/ABI-7232-2020
dc.authorwosidKorkmaz, Serdal/IST-3736-2023
dc.authorwosidBasturk, Abdulkadir/B-1962-2018
dc.authorwosidCelik, Osman/KLZ-6766-2024
dc.authorwosidBaşcı, Semih/AAB-4823-2021
dc.authorwosidDogu, Mehmet Hilmi/W-2255-2017
dc.contributor.authorYigenoglu, Tugce N.
dc.contributor.authorAta, Naim
dc.contributor.authorAltuntas, Fevzi
dc.contributor.authorBasci, Semih
dc.contributor.authorDal, Mehmet Sinan
dc.contributor.authorKorkmaz, Serdal
dc.contributor.authorNamdaroglu, Sinem
dc.date.accessioned2024-08-04T20:48:50Z
dc.date.available2024-08-04T20:48:50Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstractIn this study, we aim to report the outcomes for COVID-19 in patients with hematological malignancy in Turkey. Data from laboratory-confirmed 188 897 COVID-19 patients diagnosed between 11 March 2020 and 22 June 2020 included in the Republic of Turkey, Ministry of Health database were analyzed retrospectively. All COVID-19 patients with hematological malignancy (n = 740) were included in the study and an age, sex, and comorbidity-matched cohort of COVID-19 patients without cancer (n = 740) at a 1:1 ratio was used for comparison. Non-Hodgkin lymphoma (30.1%), myelodysplastic syndrome (19.7%), myeloproliferative neoplasm (15.7%) were the most common hematological malignancies. The rates of severe and critical disease were significantly higher in patients with hematological malignancy compared with patients without cancer (P = .001). The rates of hospital and intensive care unit (ICU) admission were higher in patients with hematological malignancy compared with the patients without cancer (P = .023,P = .001, respectively). The length of hospital stay and ICU stay was similar between groups (P = .7,P = .3, retrospectively). The rate of mechanical ventilation (MV) support was higher in patients with hematological malignancy compared with the control group (P = .001). The case fatality rate was 13.8% in patients with hematological malignancy, and it was 6.8% in the control group (P = .001). This study reveals that there is an increased risk of COVID-19-related serious events (ICU admission, MV support, or death) in patients with hematological malignancy compared with COVID-19 patients without cancer and confirms the high vulnerability of patients with hematological malignancy in the current pandemic.en_US
dc.identifier.doi10.1002/jmv.26404
dc.identifier.endpage1104en_US
dc.identifier.issn0146-6615
dc.identifier.issn1096-9071
dc.identifier.issue2en_US
dc.identifier.pmid32776581en_US
dc.identifier.scopus2-s2.0-85089856598en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1099en_US
dc.identifier.urihttps://doi.org/10.1002/jmv.26404
dc.identifier.urihttps://hdl.handle.net/11616/99487
dc.identifier.volume93en_US
dc.identifier.wosWOS:000562502800001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofJournal of Medical Virologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCOVID-19en_US
dc.subjecthematological malignancyen_US
dc.subjectSARS-CoV-2en_US
dc.titleThe outcome of COVID-19 in patients with hematological malignancyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu